Sight SciencesSGHT +0.33%72 Median PS Value is $0.00 as of Jun. 25, 2026. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.49 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 338 Medical Devices & Instruments companies, Sight Sciences ranks worse than 295857.69% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2026-06-25), Sight Sciences's share price is $5.52. Sight Sciences's Median PS Value is $0.00. Therefore, Sight Sciences's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Sight Sciences's Median PS Value or its related term are showing as below:
SGHT's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.71 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Sight Sciences (NAS:SGHT) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Sight Sciences's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
5.52
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences Median PS Value Related Terms
Sight Sciences Median PS Value Historical Data
* Premium members only.
The historical data trend for Sight Sciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sight Sciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Sight Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.507.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a Median PS Value of $0.00 as of Jun. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sight Sciences and its competitors. According to the industry distribution chart, Sight Sciences ranks #999999 out of 338 companies in the Medical Devices & Instruments industry.
Is Sight Sciences' Median PS Value too high?
Sight Sciences' current Median PS Value is $0.00. Based on the distribution chart, Sight Sciences ranks #999999 out of 338 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Median PS Value compare to QSI and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #999999 out of 338 companies for Median PS Value. This places Sight Sciences in the lower half of its industry. The industry median Median PS Value is 0.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.71, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.49, compared to a current price of $5.52 — trading 22.9% above its estimated fair value. The current Median PS Value is $0.00. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Median PS Value is $0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $5.52 is trading 22.9% above its estimated GF Value™ of $4.49.
GuruFocus considers Sight Sciences to be Modestly Overvalued.
Key valuation signals for SGHT:
Median PS Value: $0.00
GF Value™: $4.49 vs. price of $5.52 (22.9% above fair value)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score
Get the complete analysis for SGHT
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
